Minhas Gillipsie, Morishita Ryuichi, Anand Akshay
Neuroscience Research Lab, Department of Neurology, Postgraduate Institute of Medical Education and Research Chandigarh, India.
Front Neurol. 2012 May 11;3:75. doi: 10.3389/fneur.2012.00075. eCollection 2012.
Retinal ischemia is a major cause of blindness worldwide. It is associated with various disorders such as diabetic retinopathy, glaucoma, optic neuropathies, stroke, and other retinopathies. Retinal ischemia is a clinical condition that occurs due to lack of appropriate supply of blood to the retina. As the retina has a higher metabolic demand, any hindrance in the blood supply to it can lead to decreased supply of oxygen, thus causing retinal ischemia. The pathology of retinal ischemia is still not clearly known. To get a better insight into the pathophysiology of retinal ischemia, the role of animal models is indispensable. The standard treatment care for retinal ischemia has limited potential. Transplantation of stem cells provide neuroprotection and to replenish damaged cells is an emerging therapeutic approach to treat retinal ischemia. In this review we provide an overview of major animal models of retinal ischemia along with the current and preclinical treatments in use.
视网膜缺血是全球失明的主要原因。它与多种疾病相关，如糖尿病性视网膜病变、青光眼、视神经病变、中风及其他视网膜病变。视网膜缺血是一种临床病症，是由于视网膜血液供应不足所致。由于视网膜的代谢需求较高，其血液供应的任何阻碍都可导致氧气供应减少，从而引起视网膜缺血。视网膜缺血的病理机制仍不清楚。为了更好地了解视网膜缺血的病理生理学，动物模型的作用不可或缺。视网膜缺血的标准治疗方法潜力有限。干细胞移植提供神经保护并补充受损细胞是一种新兴的治疗视网膜缺血的方法。在本综述中，我们概述了主要的视网膜缺血动物模型以及目前正在使用的临床和临床前治疗方法。
